{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"9.2","value":"5.7"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"6.4","value":"5.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Median time to progression or death","dispersionType":"95% Confidence Interval","groups":[{"description":"Progression-free survival results from the phase I part of the phase I/II CCI779 with velcade study.","id":"OG000","title":"CCI779 PFS Phase I"},{"description":"Progression-free survival results from the phase II part of the phase I/II CCI779 with velcade study.","id":"OG001","title":"CCI779 PFS Phase II"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"10 months","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"month"}